Preparation, physicochemical characterization and In-Vitro dissolution studies of Diosmin-Cyclodextrin inclusion complexes

Iranian Journal of Pharmaceutical Research

Volumn 13, Issue 4, 2014, Pages 1115-1123

  Ai, Fengwei ^a   Ma, Yingli ^b   Wang, Jiayu ^b   Li, Yanfeng ^b  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Cyclodextrins; Diosmin; Dissolution rate; Inclusion complex; Solubility

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN; DIOSMIN;

ARTICLE; COMPLEX FORMATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; FREEZE DRYING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; INFRARED SPECTROSCOPY; MICROSCOPY; PARTICLE SIZE; PHYSICAL CHEMISTRY;

EID: 84907293672     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Yasuji T, Takeuchi H and Kawashima Y Particle design of poorly water-soluble drug substances using supercritical fluid technologies. Adv. Drug Deliv. Rev. (2008) 60: 388-398.
2. Yu DG, Branford-White C, White K, Li XL and Zhu LM. Dissolution improvement of electrospun nanofiber-based solid dispersions for acetaminophen. AAPS. Pharm. Sci. Tech. (2010) 11: 809-817.
3. Yano H and Kleinebudde P. Improvement of dissolution behavior for poorly water-soluble drug by application of cyclodextrin in extrusion process: comparison between melt extrusion and wet extrusion. AAPS. Pharm. Sci. Tech. (2010) 11: 885-893.
4. Loftsson T. Aqueous solubility and true solutions. Pharmazie. (2010) 65: 404-407.
5. Ficarra R, Ficarra P, Bella MRD, Raneri D, Tommasini S, Calabrò ML, Villari A and Coppolino S. Study of the inclusion complex of atenolol with β-cyclodextrins. J. Pharm. Biomed. Anal. (2000) 23: 231-236.
6. Zingone G and Rubessa F. Preformulation study of the inclusion complex warfarin-B-cyclodextrin. Int. J. Pharm. (2005) 291: 3-10.
7. Al Omari AA, Al Omari MM, Badwan AA and Al- Sou'od KA. Effect of cyclodextrins on the solubility and stability of candesartan cilexetil in solution and solid state. J. Pharm. Biomed. Anal. (2011) 54: 503509.
8. Dreassi E, Zizzari AT, Mori M, Filippi I, Belfiore A, Naldini A, Carraro F, Santucci A, Schenone S and Botta M. 2-Hydroxypropyl-beta-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors. Eur. J. Med. Chem. (2010) 45: 5958-5964.
9. Fahr A and Liu X. Drug delivery strategies for poorly water-soluble drugs. Expert. Opin. Drug Deliv. (2007) 4: 403-416.
10. Stella VJ and He Q. Cyclodextrins. Toxicol. Pathol. (2008) 36: 30-42.
11. Carrier RL, Miller LA and Ahmed I. The utility of cyclodextrins for enhancing oral bioavailability. J. Controll. Release (2007) 123: 78-99.
12. Ghodke DS, Chaulang GM, Patil KS, Nakhat PD, Yeole PG, Naikwade NS and Magdum CS. Solid state characterization of domperidone: Hydroxypropyl- beta-cyclodextrin inclusion complex. Indian J. Pharm. Sci. (2010) 72: 245-249.
13. Monograph. Diosmin. Altern. Med. Rev. (2004) 9: 308-311.
14. Ramelet AA. Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency. Angiol. (2001) 52: 49-56.
15. Meshikhes AW. Efficacy of Daflon in the treatment of hemorrhoids. Saudi. Med. J. (2002) 23: 1496-1498.
16. Pecking AP, Fevrier B, Wargon C and Pillion G. Efficacy of Daflon 500 mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer). Angiol. (1997) 48: 93-98.
17. Coleridge Smith PD. From skin disorders to venous leg ulcers: pathophysiology and efficacy of Daflon 500 mg in ulcer healing. Angiol. (2003) 54: 45-50.
18. Crespo ME, Galvez J, Cruz T, Ocete MA and Zarzeulo A. Anti-inflammatory activity of diosmin and hesperidin in rat colitis induced by TNBS. Planta. Med. (1999) 65: 651-653.
19. Ünlü A, Sucu N, Tamer L, Coskun B, Yücebilgic G, Ercan B, Gül A, Dikmengil M and Atik U. Effects of Daflon on oxidative stress induced by hindlimb ischemia/reperfusion. Pharmacol. Res. (2003) 48: 11-15.
20. Hosseinimehr SJ, Ahmadi A, Mahmoudzadeh A and Mohamadifar S. Radioprotective effects of Daflon against genotoxicity induced by gamma irradiation in human cultured lymphocytes. Environ. Mol. Mutagen. (2009) 50: 749-752.
21. Bear WL and Teel RW. Effects of citrus flavonoids on the mutagenicity of heterocyclic amines and on cytochrome P450 1A2 activity. Anticancer Res. (2000) 20: 3609-3614.
22. Wang S, Ding Y and Yao Y. Inclusion complexes of fluorofenidone with β-cyclodextrin and hydroxypropyl-β- cyclodextrin. Drug Dev. Ind. Pharm. (2009) 35: 808-813.
23. Talegaonkar S, Khan AY, Khar RK, Ahmad FJ and Khan ZI. Development and characterization of paracetamol complexes with Hydroxypropyl-β-Cyclodextrin. Iran. J. Pharm. Res. (2007) 6: 95-99.
24. El-Shafae AM and El-Domiaty MM. Improved LC methods for the determination of diosmin and/ or hesperidin in plant extracts and pharmaceutical formulations. J. Pharm. Biomed. Anal. (2001) 26: 539-545.
25. Higuchi T and Connors KA. Phase solubility techniques. Adv. Anal. Chem. Instrum. (1965) 4: 117-212.
26. Doile KM, Fortunato KA, Schmücker IC, Schucko SK, Silva MAS and Rodrigues PO. Physicochemical properties and dissolution studies of dexamethasone acetate-β-cyclodextrin inclusion complexes produced by different methods. AAPS. Pharm. Sci. Tech. (2008) 9: 314-321.
27. Khan KA. The concept of dissolution efficiency. J. Pharm. Pharmacol. (1975) 27: 48-49.